RAPT Therapeutics Inc's shares surged 63.82% in pre-market trading, reaching a 52-week high of $57.40 following GSK's announcement of its acquisition for $2.2 billion.
The acquisition agreement includes a cash price of $58.00 per share, representing a 65.2% premium over the previous closing price. This strategic move enhances GSK's portfolio in respiratory and immunology treatments, particularly with the inclusion of ozureprubart, a long-acting anti-IgE monoclonal antibody currently in Phase IIb trials, which could significantly improve treatment options for food allergies.
This acquisition not only boosts RAPT's shareholder value but also positions GSK to capture a larger share of the allergy treatment market, potentially benefiting millions of patients with food allergies in the U.S.
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 57.650
Low
56.00
Averages
67.78
High
95.00
Current: 57.650
Low
56.00
Averages
67.78
High
95.00
Barclays
Overweight -> Equal Weight
downgrade
$58
2026-01-21
Reason
Barclays
Price Target
$58
AI Analysis
2026-01-21
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Rapt Therapeutics to Equal Weight from Overweight with a $58 price target after GSK entered into an agreement to acquire all the outstanding shares of Rapt for $58 per share in cash.
Leerink
Thomas Smith
Outperform -> Market Perform
downgrade
$58
2026-01-21
Reason
Leerink
Thomas Smith
Price Target
$58
2026-01-21
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Thomas Smith downgraded Rapt Therapeutics to Market Perform from Outperform with a $58 price target after GSK entered into an agreement to acquire all the outstanding shares of Rapt for $58 per share in cash
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RAPT
Unlock Now
H.C. Wainwright
Emily Bodnar
Buy
to
Neutral
downgrade
$72 -> $58
2026-01-20
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$72 -> $58
2026-01-20
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics to Neutral from Buy with a price target of $58, down from $72, after GSK entered into an agreement to acquire all outstanding shares of Rapt for $58 per share in cash. The firm views the acquisition as "logical."
LifeSci Capital
Outperform -> Market Perform
downgrade
$58
2026-01-20
Reason
LifeSci Capital
Price Target
$58
2026-01-20
downgrade
Outperform -> Market Perform
Reason
LifeSci Capital downgraded Rapt Therapeutics to Market Perform from Outperform after GSK entered into an agreement to acquire all outstanding shares of Rapt for $58 per share in cash.
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
